Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2351)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (101)
  6. Guidelines (40)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (23)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4749)
  2. Department of Medicine (4747)
  3. Center for Pancreatic Cancer Research (2316)
  4. Surgery (1067)
  5. Survivorship Research (1014)
  6. Epidemiology and Biostatistics (843)

More Groups

People
  1. Eileen O'Reilly (804)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (224)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (148)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (322)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4749)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
    Meeting Abstract

    Hammel, P.; Kindler, H. L.; Reni, M.; Van Cutsem, E.; Mercade, T. M.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    Rimassa, L.; Kelley, R. K.; Meyer, T.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Blanc, J. F.; Lim, H. Y.; Tran, A.; Borgman-Hagey, A. E.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt)
    Meeting Abstract

    Rousseau, B. J. C.; Cohen, J.; Calderaro, J.; Dupuy, A.; Bourgoin, R.; Tournigand, C.; Baumgaertner, I.; Ropert, S.; Thirot Bidault, A.; Klotz, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
    Meeting Abstract

    Strickler, J. H.; Zemla, T.; Ou, F. S.; Cercek, A.; Wu, C.; Sanchez, F. A.; Hubbard, J.; Jaszewski, B.; Bandel, L.; Schweitzer, B.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses
    Meeting Abstract

    Tempero, M. A.; Reni, M.; Riess, H.; O'Reilly, E. M.; Krishnamurthi, S.; Österlund, P.; Ales-Diaz, I. C.; Milella, M.; Siena, S.; Tabernero, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
    Meeting Abstract

    Schram, A. M.; Drilon, A.; Macarulla Mercade, T.; O'Reilly, E. M.; Rodon, J. A.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C. H.; Lam, Y. C. J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    Meyer, T.; Kelley, R. K.; Mangeshkar, M.; Cheng, A. L.; El-Khoueiry, A. B.; Abou-Alfa, G. K.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies
    Meeting Abstract

    Diaz, L. A.; Le, D.; Maio, M.; Ascierto, P. A.; Geva, R.; Motola-Kuba, D.; André, T.; Van Cutsem, E.; Gottfried, M.; Elez, E.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Bendell, J.; Lieu, C.; Raghav, K. P. S.; Argilés, G.; Cubillo, A.; Qu, X.; Yan, Y.; Merchant, M.; Zeuner, H.; Gallo, J. D.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save